EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol

Spiros Arampatzis, Thomas Ernandez iD, Daniel Teta, Marco Bonani, Argyrios Georgalis, Stefan Flury, Antonio Bellasi iD

Journal of Nephrology · 2026

DOI: 10.1093/joneph/aajaf008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Spiros Arampatzis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bern Dialysis and Lindenhof Hospital Dialysis Center, Bern, Switzerland. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic, Calcifediol, Vitamin D Deficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vifor Pharma Switzerland SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article examines the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease (NDD-CKD) patients in Switzerland, with a focus on optimizing bone and mineral health in CKD stages 3–4. The impact of vitamin D insufficiency on secondary hyperparathyroidism is discussed and current treatment options and challenges are explored. To support clinical practice, current secondary hyperparathyroidism management was analyzed, emphasizing monitoring practices for bone and mineral parameters alongside guidelines for prescribing vitamin D-based therapies. A treatment algorithm incorporating extended-release calcifediol, as well as insights from KDIGO (Kidney Disease: Improving Global Outcomes) for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), are presented to refine therapeutic approaches. Key findings illustrate the absence of definitive clinical endpoints, leading to the proposed use of a 25(OH)D threshold <30 ng/mL (<75 nmol/L) to guide treatment initiation. Target 25(OH)D concentrations between 30–100 ng/mL (75–250 nmol/L) are advocated, with the 30 ng/mL level serving as a practical reference for CKD patients, consistent with KDIGO recommendations. While extended-release calcifediol has demonstrated biochemical efficacy in raising 25(OH)D and reducing parathyroid hormone levels, high-dose cholecalciferol has also shown efficacy, though data remain heterogeneous. These insights address the clinical relevance and provide actionable guidance for achieving and maintaining adequate vitamin D levels through the administration of extended-release calcifediol. This review underscores the importance of structured monitoring, evidence-based therapy initiation, and individualized care to improve bone and mineral metabolism in NDD-CKD patients, contributing to better long-term outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, SecondaryRenal Insufficiency, ChronicCalcifediolVitamin D DeficiencyCalcium-Regulating Hormones and AgentsHumansDelayed-Action PreparationsVitamin DTreatment OutcomeParathyroid HormoneBiomarkers

Stichwörter der Autor:innen

extended-release calcifediol (ERC)non-dialysis dependent chronic kidney disease (NDD-CKD)secondary hyperparathyroidism (sHPT)treatment guidelinesvitamin D insufficiency (VDI)

Substanzen

Delayed-Action PreparationsCalcifediolVitamin DParathyroid HormoneBiomarkersCalcium-Regulating Hormones and Agents

Autor:innen und Institutionen

  • Bern Dialysis and Lindenhof Hospital Dialysis Center, Bern, Switzerland.
  • Service of Nephrology, Department of Medical Specialties, University Hospital of Geneva, Geneva, Switzerland.
  • Nephrology and Dialysis Center, Prilly/Lausanne, Switzerland.
  • Service of Nephrology, Sion Hospital, Sion, Switzerland.
  • Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Nephrology/Dialysis, Cantonal Hospital Glarus, Glarus, Switzerland.

ORCID-Profile: Thomas Ernandez, Antonio Bellasi

Förderung

  • Vifor Pharma Switzerland SA

Zitieren

APA

Arampatzis, S., Ernandez, T., Teta, D., Bonani, M., Georgalis, A., Flury, S., & Bellasi, A. (2026). New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol. Journal of Nephrology. https://doi.org/10.1093/joneph/aajaf008

Vancouver

Arampatzis S, Ernandez T, Teta D, Bonani M, Georgalis A, Flury S, et al. New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol. Journal of Nephrology. 2026. doi:10.1093/joneph/aajaf008

BibTeX
@article{Arampatzis2026,
  author = {Arampatzis, Spiros and Ernandez, Thomas and Teta, Daniel and Bonani, Marco and Georgalis, Argyrios and Flury, Stefan and Bellasi, Antonio},
  title = {New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol},
  journal = {Journal of Nephrology},
  year = {2026},
  doi = {10.1093/joneph/aajaf008}
}
Kostenlos starten →